ProCE Banner Activity

CDK4/6 Inhibitors in the Management of HR+/HER2- MBC

Slideset Download
Download this slideset to review the latest clinical data informing optimal use of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer.

Released: May 31, 2019

Expiration: May 29, 2020

Share

Supporters

Lilly

Novartis Pharmaceuticals Corporation